enatide, n/H1100527; 5/H9262g exenatide, n/H1100527; placebo, n/H11005 23. Subjects in the 10- /H9262g exenatide b.i.d. arm received 5/H9262g exenatide b.i.d. during weeks 0 â€“ 4. Subjects in all treatment arms were maintained on metformin-sulfonylurea therapy. Data are means /H11006SE.Exenatide and glycemic control 1088 DIABETES CARE,VOLUME 28, NUMBER 5, M AY2005